Larimar Therapeutics, Inc. (LRMR)
$ 10
-0.27 (-2.63%)
-
| Symbol | LRMR |
|---|---|
| Price | $ 10 |
| Beta | 0.823 |
| Volume Avg. | 0.05M |
| Market Cap | 0.177B |
| Shares () | - |
| 52 Week Range | 7.0-24.082 |
| 1y Target Est | - |
| DCF Unlevered | LRMR DCF -> | |
|---|---|---|
| DCF Levered | LRMR LDCF -> | |
| ROE | -58.08% | Strong Sell |
| ROA | -60.76% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 19.85% | Neutral |
| P/E | - | |
| P/B | 2.37 | Strong Buy |
Latest LRMR news
About
Download (Excel)Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound is CTI-1601, a Phase 1 clinical program to treat Friedreich's ataxia, a rare and progressive genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.